Purpose The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [ 
Introduction
Renal cell carcinoma (RCC) accounts for 2% of all malignancies worldwide, with an estimated 403,262 new cases in 2018. Seventy percent have a clear cell component. Metastatic clear cell (mcc) RCC has a variable course, with a subgroup of patients showing slow disease progression. In those patients, it is safe to observe the course of disease in a period of socalled watchful waiting, avoiding unnecessary side-effects and costs of systemic treatment.
To identify patients eligible for watchful waiting, prognostic schemes such as the International Metastatic Database Consortium (IMDC) risk model have been used to differentiate between patients with a good, intermediate or poor prognosis [1, 2] . For staging mRCC, European Society of Medical Oncology (ESMO) guidelines mandate contrast-enhanced computed tomography (CT) of chest, abdomen and pelvis [3] .
Previously, an international phase II study in mRCC patients eligible for watchful waiting showed that higher numbers of IMDC adverse risk factors (p = 0.0403) and higher numbers of metastatic disease organ sites (p = 0.0414) were associated with a shorter period of watchful waiting [4] . These results substantiate the clinical value of imaging, which may be further enhanced by molecular imaging with [ CAIX is over-expressed in 94% of ccRCC-tumors due to a mutational loss of Von Hippel Lindau protein [5] [6] [7] . Prognostic implications of immunohistochemically determined CAIX-expression are unequivocal [7] [8] [9] [10] [11] [12] . In-vivo assessment of CAIX-expression can be performed with radiolabeled girentuximab (anti-CAIX antibody) PET-imaging. This technique visualizes primary and metastatic ccRCC lesions [13] [14] [15] 
Materials and methods

Patients
In this prospective multicenter cohort study, patients aged 18 years and older with histologically or cytologically proven RCC with a clear cell component, recently (<6 months) diagnosed metastases, and a good or intermediate prognosis according to IMDC score [1] , were enrolled in the IMPACT-RCC study conducted at four Dutch academic medical centers. A period of watchful waiting for 2 months was considered optional according to treating medical oncologist. Patients who received any previous systemic treatment for RCC in any setting were excluded, but previous radiotherapy and surgery (nephrectomy or metastasectomy) was permitted. Furthermore, patients were excluded in the presence of untreated central nervous system metastases or symptomatic intra-cerebral metastases, pregnant or breast feeding women. Only patients without prior systemic treatment were enrolled, therefore the IMDC criteria 'time from diagnosis to treatment <1 year' was adapted into 'time from primary diagnosis to diagnosis of metastatic disease <1 year'. Watchful waiting was terminated if radiological disease progression was established, in combination with a clinical need to start systemic treatment. 
Patient imaging
Statistical analysis
To compare the agreement in individual lesion detection between observers, we used dependent pair wise or multiobservers kappa-coefficients with the delta method [19] . Lesion detection rates per imaging modality and combined imaging modalities (CT combined with PET/CT) were estimated and compared (by Wald tests) using mixed effect logistic regression models accounting for within patient and lesionclustering by random intercepts. We evaluated lesion detection rates overall and according to organ sites. Furthermore, we compared the median number of affected organ sites across patients assessed by CT only, or in conjunction with either PET/CT using Wilcoxon signed rank tests.
To assess biodistribution of [
89 Zr]Zr-DFO-girentuximab, we estimated the average SUV mean per organ and compared variability within and between patients (one-sample T-test). SUV max was evaluated using descriptive methods besides mixed effects linear regression models, taking within patient clustering into account as random intercepts (using intra-class correlation coefficient (ICC) to estimate variation in uptake due to between-patient heterogeneity). These models were also used to assess determinants of tracer-uptake (introduced as fixed effects and compared by Wald tests). SUV max was natural log-transformed to obtain appropriate model fit, resulting in geometric means or percent changes in SUV max as interpretation of fixed effects. We fitted these models under restricted maximum likelihood using Satterthwaite approximations to degrees of freedom. We used the marginal R 2 to estimate the variance in tracer-uptake explained by the fixed effects of these models [20] , then fitted under maximum likelihood.
We report estimates with 95% confidence intervals (CI), and statistical tests were two-sided with threshold for significance of 5%, without adjusting for multiple testing. Analyses were performed in R (version 3.2.1), particularly using libraries multi-agree (version 2.1), lme4 (version1.1-11), lmerTest (version2.0-20), and MuMIn (version1.10.0).
Results
Patients
From February 2015 until March 2018, 42 mccRCC patients were included. All patients had a histopathological diagnosis of the primary tumor, either through (partial) nephrectomy or biopsy in 36 and six patients, respectively. A total of 14 patients had a favourable prognosis. Of the remaining 28 patients, 13 had a predicted intermediate prognosis with one risk factor and 15 patients with two risk factors. This was primarily due to the diagnosis of metastases <1 year after the primary diagnosis (80%) and/or the presence of anaemia (51%). There was no correlation between histology (e.g. mixed vs. pure clear cell) and the estimated prognosis according to IMDC.
All patients without a previous nephrectomy had an estimated intermediate prognosis. In total 57% of all patients presented with metachronous metastases at a median interval of 0.7 (range 0-15) months between primary diagnosis and first metastasis. One patient presented with only sub-centimeter indeterminate lung lesions; therefore, lesions were not included in the analyses. Five others had a negative [ Patient characteristics are shown in Table 1 , imaging examples are shown in Fig. 1 8 9 Zr]Zr-DFOgirentuximab-PET/CT visualized 70% (95%CI 64-75), which was more than CT alone (p < 0.001) or [ -88) , respectively. Improved lesion detection rate was apparent for all organ sites (Fig. 2) . The lesion detection of CT-[ (Table 2) . Patients were categorized according to the location of their lesions (e.g. lung only; other organ(s) only and both lung and other organs). With the addition of both PET/CTs, two patients were re-categorized from lung only into 'both lung and other organs' based on the additional detected lymph node and bone lesions ( Concordant pairs were lesions that were visualized on all three modalities. Nine PET detected lesions were outside the field of view of CT. *p < 0.001 compared to CT only lesions (median SUV max 61.1 and 69.9, respectively) and lowest in lung lesions (median SUV max 9.4) (Fig. 3) A patient's prognosis is estimated based on the number of involved organs on CT, total disease burden and period of watchful waiting, rather than the number of lesions [4, 21] . In our study population 33% of the patients present with a predicted good prognosis mRCC and 43% of patients with synchronous metastases. This is comparable to previous datasets and reflects daily clinical practice [4] . Patients with lung-only metastases are thought to have a better prognosis than other involved organ sites such as liver and bone [22, 23] . In our study population, based on CT only, seven patients (17%) presented with lungonly metastases. This number was revised after the addition of PET/CT because of the detection of additional bone and lymph node lesions by PET/CT in two patients. Furthermore, two patients were diagnosed with brain metastases by [ Overall, the median number of two involved organs per patient as determined by CT alone increased to three per patient with the addition of PET/CT (range 1-7; p < 0.005), even without adjusting for the limited CT field-of-view. This is largely attributed to the detection of more soft-tissue and bone lesions, a well-known limitation of CT due to less soft tissue contrast and the limited ability to detect (non-lytic) bone lesions. This limited increase in the number of involved organ sites with the addition of PET/CT questions its additional value, since solely an increase in detection lesions will not lead to the implementation of [
89 Zr]Zr-DFO-girentuximab or [ 18 F]FDG-PET/CT to our standard work-up. However, The interpretation of involved organ sites in all three modalities was challenging, especially considering the limitation of each modality. For example, spatial resolution is lower with PET/CT compared to CT, resulting in a partial volume effect affecting small (<2 cm), low-contrast lesions both visually and quantitatively [24] . CT can detect sub-centimeter or indeterminate pulmonary nodules and lymph nodes, although distinguishing nonspecific from small metastatic lesions with CT is notoriously difficult. Based on studies of pulmonary metastases in RCC and RECIST 1.1 criteria, we used a diameter cut-off of 10 mm and in lymph nodes 15 mm to prevent overestimating of the number of detected lesions [25, 26] . This ultimately reduced the number of (small) lung and lymph node lesions detected by CT, thereby underestimating the overall lesion detection by CT. 89 Zr]Zr-DFO-girentuximab-PET/CT in the early detection of mccRCC lesions [27] . Furthermore, the quantification of tracer-uptake in both PET-imaging modalities offers a better understanding of the heterogenic study population [4] . Combining anatomical imaging techniques with functional imaging techniques targeting glucose metabolism and CAIX expression offers a better representation of the heterogeneity by visualizing whole body tumor nature and active metabolic processes (e.g. glycolysis, GLUT-1-expression) [8] .
Upon completion of the follow-up data of all patients included in the IMPACT-RCC study, we will analyze whether [ 
